232 related articles for article (PubMed ID: 36866734)
1. Eosinophilic respiratory disorders and the impact of biologics.
Bernstein JS; Wechsler ME
Curr Opin Pulm Med; 2023 May; 29(3):202-208. PubMed ID: 36866734
[TBL] [Abstract][Full Text] [Related]
2. Targeted Molecular Therapies in Allergy and Rhinology.
Damask CC; Ryan MW; Casale TB; Castro M; Franzese CB; Lee SE; Levy JM; Lin SY; Lio PA; Peters AT; Platt MP; White AA
Otolaryngol Head Neck Surg; 2021 Jan; 164(1_suppl):S1-S21. PubMed ID: 33138725
[TBL] [Abstract][Full Text] [Related]
3. Current and emerging biologic therapies targeting eosinophilic disorders.
Pitlick MM; Li JT; Pongdee T
World Allergy Organ J; 2022 Aug; 15(8):100676. PubMed ID: 35983569
[TBL] [Abstract][Full Text] [Related]
4. Eosinophilia Induced by Blocking the IL-4/IL-13 Pathway: Potential Mechanisms and Clinical Outcomes.
Olaguibel JM; Sastre J; Rodríguez JM; Del Pozo V
J Investig Allergol Clin Immunol; 2022 Jun; 32(3):165-180. PubMed ID: 35522053
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
Nolasco S; Portacci A; Campisi R; Buonamico E; Pelaia C; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Crimi N; Scichilone N; Pelaia G; Carpagnano GE; Crimi C
Front Immunol; 2023; 14():1204444. PubMed ID: 37457743
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review.
Raffray L; Guillevin L
Drugs; 2018 Jun; 78(8):809-821. PubMed ID: 29766394
[TBL] [Abstract][Full Text] [Related]
7. Treatments of refractory eosinophilic lung diseases with biologics.
Asano K; Suzuki Y; Tanaka J; Kobayashi K; Kamide Y
Allergol Int; 2023 Jan; 72(1):31-40. PubMed ID: 36333218
[TBL] [Abstract][Full Text] [Related]
8. A pragmatic guide to choosing biologic therapies in severe asthma.
Kavanagh JE; Hearn AP; Jackson DJ
Breathe (Sheff); 2021 Dec; 17(4):210144. PubMed ID: 35296105
[TBL] [Abstract][Full Text] [Related]
9. Adult-onset eosinophilic airway diseases.
Asano K; Ueki S; Tamari M; Imoto Y; Fujieda S; Taniguchi M
Allergy; 2020 Dec; 75(12):3087-3099. PubMed ID: 33040364
[TBL] [Abstract][Full Text] [Related]
10. Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders.
Olivieri B; Tinazzi E; Caminati M; Lunardi C
Immunol Allergy Clin North Am; 2020 Nov; 40(4):649-665. PubMed ID: 33012326
[TBL] [Abstract][Full Text] [Related]
11. From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.
Pavord ID; Bel EH; Bourdin A; Chan R; Han JK; Keene ON; Liu MC; Martin N; Papi A; Roufosse F; Steinfeld J; Wechsler ME; Yancey SW
Allergy; 2022 Mar; 77(3):778-797. PubMed ID: 34402066
[TBL] [Abstract][Full Text] [Related]
12. Advancements in biologic therapy in eosinophilic asthma.
Patadia R; Casale TB; Fowler J; Patel S; Cardet JC
Expert Opin Biol Ther; 2024 Apr; 24(4):251-261. PubMed ID: 38619468
[TBL] [Abstract][Full Text] [Related]
13. Biologics in allergic rhinitis.
Bayar Muluk N; Cingi C
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(5 Suppl):43-52. PubMed ID: 37869947
[TBL] [Abstract][Full Text] [Related]
14. Biologic Therapies for Allergic Rhinitis and Nasal Polyposis.
Geng B; Dilley M; Anterasian C
Curr Allergy Asthma Rep; 2021 Jun; 21(6):36. PubMed ID: 34110505
[TBL] [Abstract][Full Text] [Related]
15. Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases.
Del Pozo V; Bobolea I; Rial MJ; Espigol-Frigolé G; Solans Laqué R; Hernández-Rivas JM; Mora E; Crespo-Lessmann A; Izquierdo Alonso JL; Domínguez Sosa MS; Maza-Solano J; Atienza-Mateo B; Bañas-Conejero D; Moure AL; Rúa-Figueroa Í
Front Immunol; 2023; 14():1310211. PubMed ID: 38250075
[TBL] [Abstract][Full Text] [Related]
16. Severe Asthma and Biologics: Managing Complex Patients.
Matucci A; Micheletto C; Vultaggio A
J Investig Allergol Clin Immunol; 2023 Jun; 33(3):168-178. PubMed ID: 36059229
[TBL] [Abstract][Full Text] [Related]
17. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
[TBL] [Abstract][Full Text] [Related]
18. Biologics for eosinophilic granulomatosis with polyangiitis.
Caminati M; Maule M; Bello F; Emmi G
Curr Opin Allergy Clin Immunol; 2023 Feb; 23(1):36-43. PubMed ID: 36413432
[TBL] [Abstract][Full Text] [Related]
19. Combination of monoclonal antibodies targeting type 2 inflammation for severe asthma and eosinophilic granulomatosis with polyangiitis.
Davanzo F; Marchi MR; Iorio L; Bortoli M; Doria A; Padoan R
Autoimmun Rev; 2024 Mar; 23(3):103503. PubMed ID: 38101691
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
